Axsome Therapeutics (AXSM) Revenue & Revenue Breakdown
Axsome Therapeutics Revenue Highlights
Latest Revenue (Y)
$385.69M
Latest Revenue (Q)
$87.17M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Axsome Therapeutics Revenue by Period
Axsome Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $385.69M | 42.53% |
| 2023-12-31 | $270.60M | 440.80% |
| 2022-12-31 | $50.04M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | - |
Axsome Therapeutics generated $385.69M in revenue during NA 2024, up 42.53% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Axsome Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $87.17M | 16.22% |
| 2024-03-31 | $75.00M | 4.85% |
| 2023-12-31 | $71.53M | 23.77% |
| 2023-09-30 | $57.79M | 23.76% |
| 2023-06-30 | $46.70M | -50.62% |
| 2023-03-31 | $94.58M | 288.06% |
| 2022-12-31 | $24.37M | 44.67% |
| 2022-09-30 | $16.85M | 91.00% |
| 2022-06-30 | $8.82M | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | - |
Axsome Therapeutics generated $87.17M in revenue during Q2 2024, up 16.22% compared to the previous quarter, and up 92.17% compared to the same period a year ago.
Axsome Therapeutics Revenue Breakdown
Axsome Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 |
|---|---|---|
| Product | $381.68M | $202.46M |
| Royalty | - | $2.40M |
| License | - | $65.73M |
Axsome Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 |
|---|---|---|---|---|---|---|---|
| Product | $203.84M | $103.74M | $74.10M | $70.75M | $57.13M | $46.02M | $28.57M |
| Royalty | - | $1.03M | $903.00K | $783.00K | $667.00K | $683.00K | $272.00K |
| License | - | - | - | - | $65.73M | $65.73M | - |
Axsome Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Product (100.00%).
Axsome Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 | Dec 22 |
|---|---|---|---|
| Non-US | $4.02M | $65.73M | $900.00K |
| UNITED STATES | $378.16M | $197.22M | - |
Axsome Therapeutics's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (98.95%), and Non-US (1.05%).
Quarterly Revenue by Country
| Country | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 |
|---|---|---|---|---|---|---|---|
| Non-US | $2.09M | $1.03M | $903.00K | - | $65.73M | $600.00K | $1.70M |
| UNITED STATES | $202.08M | $102.81M | $73.27M | $141.44M | $55.78M | - | - |
Axsome Therapeutics's latest quarterly revenue breakdown by geography, as of Dec 24: UNITED STATES (98.98%), and Non-US (1.02%).
Axsome Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INCY | Incyte | $4.24B | $962.99M |
| SRPT | Sarepta Therapeutics | $1.90B | $362.93M |
| ACAD | ACADIA Pharmaceuticals | $957.80M | $250.40M |
| BPMC | Blueprint Medicines | $508.82M | $128.18M |
| AXSM | Axsome Therapeutics | $385.69M | $87.17M |
| MDGL | Madrigal Pharmaceuticals | $180.13M | $62.17M |
| DAWN | Day One Biopharmaceuticals | $131.16M | $20.07M |
| AMLX | Amylyx Pharmaceuticals | $87.37M | $416.00K |
| MCRB | Seres Therapeutics | - | - |
| AKRO | Akero Therapeutics | - | - |
| VKTX | Viking Therapeutics | - | - |
| TGTX | TG Therapeutics | - | $83.88M |
| PDSB | PDS Bio | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
| TERN | Terns Pharmaceuticals | - | - |